Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia von Hochhaus, Andreas, Larson, Richard A, Guilhot, François, Radich, Jerald P, Branford, Susan, Hughes, Timothy P, Baccarani, Michele, Deininger, Michael W, Cervantes, Francisco, Fujihara, Satoko, Ortmann, Christine-Elke, Menssen, Hans D, Kantarjian, Hagop, O’Brien, Stephen G, Druker, Brian J

Volltext

Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation von Burslem, George M, Schultz, Anna Reister, Bondeson, Daniel P, Eide, Christopher A, Savage Stevens, Samantha L, Druker, Brian J, Crews, Craig M

Volltext

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells von Nechiporuk, Tamilla, Kurtz, Stephen E, Nikolova, Olga, Liu, Tingting, Jones, Courtney L, D'Alessandro, Angelo, Culp-Hill, Rachel, d'Almeida, Amanda, Joshi, Sunil K, Rosenberg, Mara, Tognon, Cristina E, Danilov, Alexey V, Druker, Brian J, Chang, Bill H, McWeeney, Shannon K, Tyner, Jeffrey W

Volltext

The development of imatinib as a therapeutic agent for chronic myeloid leukemia von Deininger, Michael, Buchdunger, Elisabeth, Druker, Brian J.

Volltext

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia von Traer, Elie, Martinez, Jacqueline, Javidi-Sharifi, Nathalie, Agarwal, Anupriya, Dunlap, Jennifer, English, Isabel, Kovacsovics, Tibor, Tyner, Jeffrey W, Wong, Melissa, Druker, Brian J

Volltext

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms von Zhang, Haijiao, Savage, Samantha, Schultz, Anna Reister, Bottomly, Daniel, White, Libbey, Segerdell, Erik, Wilmot, Beth, McWeeney, Shannon K., Eide, Christopher A., Nechiporuk, Tamilla, Carlos, Amy, Henson, Rachel, Lin, Chenwei, Searles, Robert, Ho, Hoang, Lam, Yee Ling, Sweat, Richard, Follit, Courtney, Jain, Vinay, Lind, Evan, Borthakur, Gautam, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop M., Cortes, Jorge, Collins, Robert, Buelow, Daelynn R., Baker, Sharyn D., Druker, Brian J., Tyner, Jeffrey W.

Volltext

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias von Cortes, Jorge E, Kantarjian, Hagop, Shah, Neil P, Bixby, Dale, Mauro, Michael J, Flinn, Ian, O'Hare, Thomas, Hu, Simin, Narasimhan, Narayana I, Rivera, Victor M, Clackson, Tim, Turner, Christopher D, Haluska, Frank G, Druker, Brian J, Deininger, Michael W.N, Talpaz, Moshe

Volltext

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia von Carey, Alyssa, Edwards, David K., Eide, Christopher A., Newell, Laura, Traer, Elie, Medeiros, Bruno C., Pollyea, Daniel A., Deininger, Michael W., Collins, Robert H., Tyner, Jeffrey W., Druker, Brian J., Bagby, Grover C., McWeeney, Shannon K., Agarwal, Anupriya

Volltext

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer von Drilon, Alexander, Somwar, Romel, Wagner, Jacob P, Vellore, Nadeem A, Eide, Christopher A, Zabriskie, Matthew S, Arcila, Maria E, Hechtman, Jaclyn F, Wang, Lu, Smith, Roger S, Kris, Mark G, Riely, Gregory J, Druker, Brian J, O'Hare, Thomas, Ladanyi, Marc, Davare, Monika A

Volltext

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia von Branford, Susan, Kim, Dennis Dong Hwan, Apperley, Jane F., Eide, Christopher A., Mustjoki, Satu, Ong, S. Tiong, Nteliopoulos, Georgios, Ernst, Thomas, Chuah, Charles, Gambacorti-Passerini, Carlo, Mauro, Michael J., Druker, Brian J., Kim, Dong-Wook, Mahon, Francois-Xavier, Cortes, Jorge, Radich, Jerry P., Hochhaus, Andreas, Hughes, Timothy P.

Volltext

Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib von Latifi, Yllka, Moccetti, Federico, Wu, Melinda, Xie, Aris, Packwood, William, Qi, Yue, Ozawa, Koya, Shentu, Weihui, Brown, Eran, Shirai, Toshiaki, McCarty, Owen J., Ruggeri, Zaverio, Moslehi, Javid, Chen, Junmei, Druker, Brian J., López, Jose A., Lindner, Jonathan R.

Volltext

Understanding Drug Sensitivity and Tackling Resistance in Cancer von Tyner, Jeffrey W, Haderk, Franziska, Kumaraswamy, Anbarasu, Baughn, Linda B, Van Ness, Brian, Liu, Song, Marathe, Himangi, Alumkal, Joshi J, Bivona, Trever G, Chan, Keith Syson, Druker, Brian J, Hutson, Alan D, Nelson, Peter S, Sawyers, Charles L, Willey, Christopher D

Volltext

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interf... von Hughes, Timothy P., Hochhaus, Andreas, Branford, Susan, Müller, Martin C., Kaeda, Jaspal S., Foroni, Letizia, Druker, Brian J., Guilhot, François, Larson, Richard A., O'Brien, Stephen G., Rudoltz, Marc S., Mone, Manisha, Wehrle, Elisabeth, Modur, Vijay, Goldman, John M., Radich, Jerald P.

Volltext

Translation of the Philadelphia chromosome into therapy for CML von Druker, Brian J.

Volltext

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors von Davare, Monika A., Vellore, Nadeem A., Wagner, Jacob P., Eide, Christopher A., Goodman, James R., Drilon, Alexander, Deininger, Michael W., O’Hare, Thomas, Druker, Brian J.

Volltext

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes von Hosseini, Mona M., Kurtz, Stephen E., Abdelhamed, Sherif, Mahmood, Shawn, Davare, Monika A., Kaempf, Andy, Elferich, Johannes, McDermott, Jason E., Liu, Tao, Payne, Samuel H., Shinde, Ujwal, Rodland, Karin D., Mori, Motomi, Druker, Brian J., Singer, Jack W., Agarwal, Anupriya

Volltext

Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia von Packer, Leisl M., Rana, Sareena, Hayward, Robert, O'Hare, Thomas, Eide, Christopher A., Rebocho, Ana, Heidorn, Sonja, Zabriskie, Matthew S., Niculescu-Duvaz, Ion, Druker, Brian J., Springer, Caroline, Marais, Richard

Volltext

Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia von Bicocca, Vincent T., Chang, Bill H., Masouleh, Behzad Kharabi, Muschen, Markus, Loriaux, Marc M., Druker, Brian J., Tyner, Jeffrey W.

Volltext

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance von Javidi-Sharifi, Nathalie, Traer, Elie, Martinez, Jacqueline, Gupta, Anu, Taguchi, Takehiro, Dunlap, Jennifer, Heinrich, Michael C, Corless, Christopher L, Rubin, Brian P, Druker, Brian J, Tyner, Jeffrey W

Volltext

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia von Druker, Brian J, Guilhot, François, O'Brien, Stephen G, Gathmann, Insa, Kantarjian, Hagop, Gattermann, Norbert, Deininger, Michael W.N, Silver, Richard T, Goldman, John M, Stone, Richard M, Cervantes, Francisco, Hochhaus, Andreas, Powell, Bayard L, Gabrilove, Janice L, Rousselot, Philippe, Reiffers, Josy, Cornelissen, Jan J, Hughes, Timothy, Agis, Hermine, Fischer, Thomas, Verhoef, Gregor, Shepherd, John, Saglio, Giuseppe, Gratwohl, Alois, Nielsen, Johan L, Radich, Jerald P, Simonsson, Bengt, Taylor, Kerry, Baccarani, Michele, So, Charlene, Letvak, Laurie, Larson, Richard A

Volltext